TB 592 - Twinpig Biolab
Alternative Names: TB-592 - Twinpig BiolabLatest Information Update: 15 Oct 2024
Price :
$50 *
At a glance
- Originator Twinpig Biolab
- Class Obesity therapies; Peptide drug conjugates
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 25 Sep 2024 Twinpig Biolab has patents pending for preventing and treating obesity with phospholipase A2 in several countries
- 25 Sep 2024 Preclinical trials in Obesity in South Korea (unspecified route) (Twinpig Biolab pipeline, September 2024)
- 25 Sep 2024 Twinpig Biolab anticipates approval of TB 592 by the regulatory authority for Obesity by the end of 2028 (Twinpig Biolab pipeline, September 2024)